Market's view on E-therapeutics
Published on April 2024
- The recent behaviour of certain directors has been critiqued, specifically concerning their history of managing companies and the perceived negative impact on shareholder value.
- Concerns were raised about the potential delisting from AIM and the impact on investments, especially within ISAs.
- Skepticism was expressed regarding the potential NASDAQ listing, particularly given the short notice and timing over the holiday period for the delisting announcement.
- Doubts about the effectiveness of artificial intelligence in drug discovery were voiced, noting the hyped claims and limited success in securing substantial contracts.
- Frustration was evident regarding the management’s focus on raising capital which could lead to further dilution of shares without apparent benefits to current shareholders.
- Comparisons were made with other companies like Silence Therapeutics, noting similar paths and outcomes which have not necessarily benefitted shareholders.
- The process and consequences of a company going private were questioned, with concerns about the ability to trade shares post-delisting.
- The increase in holdings by Lombard Odier was noted, contrasting with the generally negative sentiment surrounding the company’s strategic decisions.
- The overall sentiment was one of dissatisfaction and caution towards the company’s future decisions and their implications for shareholders.